Schering PEG-Intron/Rebetol U.S. Filing Slated For First Quarter 2001
Executive Summary
Schering-Plough's U.S. filing for PEG-Intron (peginterferon alfa-2b) in combination with Rebetol (ribavirin) for the treatment of chronic hepatitis C is expected in the first quarter of 2001.
You may also be interested in...
Schering PEG-Intron Phase IV Trial To Study African Americans
Schering-Plough will study whether the hepatitis C treatment PEG-Intron produces lower response rates in African American patients following approval of the pegylated interferon.
Schering PEG-Intron Phase IV Trial To Study African Americans
Schering-Plough will study whether the hepatitis C treatment PEG-Intron produces lower response rates in African American patients following approval of the pegylated interferon.
Amgen Aranesp, Anakinra Could Lead 2001 Biologics Approvals
Amgen anticipates approval for two new biologics in 2001, the red blood cell stimulating factor Aranesp and the interleukin-1 receptor antagonist anakinra.